Adjuvant atezolizumab-bevacizumab after curative therapy for hepatocellular carcinoma
Autor principal: | |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
AME Publishing Company
2023
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10282679/ https://www.ncbi.nlm.nih.gov/pubmed/37351140 http://dx.doi.org/10.21037/hbsn-23-203 |
_version_ | 1785061179967668224 |
---|---|
author | Kudo, Masatoshi |
author_facet | Kudo, Masatoshi |
author_sort | Kudo, Masatoshi |
collection | PubMed |
description | |
format | Online Article Text |
id | pubmed-10282679 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2023 |
publisher | AME Publishing Company |
record_format | MEDLINE/PubMed |
spelling | pubmed-102826792023-06-22 Adjuvant atezolizumab-bevacizumab after curative therapy for hepatocellular carcinoma Kudo, Masatoshi Hepatobiliary Surg Nutr Editorial Commentary AME Publishing Company 2023-05-22 2023-06-01 /pmc/articles/PMC10282679/ /pubmed/37351140 http://dx.doi.org/10.21037/hbsn-23-203 Text en 2023 Hepatobiliary Surgery and Nutrition. All rights reserved. https://creativecommons.org/licenses/by-nc-nd/4.0/Open Access Statement: This is an Open Access article distributed in accordance with the Creative Commons Attribution-NonCommercial-NoDerivs 4.0 International License (CC BY-NC-ND 4.0), which permits the non-commercial replication and distribution of the article with the strict proviso that no changes or edits are made and the original work is properly cited (including links to both the formal publication through the relevant DOI and the license). See: https://creativecommons.org/licenses/by-nc-nd/4.0 (https://creativecommons.org/licenses/by-nc-nd/4.0/) . |
spellingShingle | Editorial Commentary Kudo, Masatoshi Adjuvant atezolizumab-bevacizumab after curative therapy for hepatocellular carcinoma |
title | Adjuvant atezolizumab-bevacizumab after curative therapy for hepatocellular carcinoma |
title_full | Adjuvant atezolizumab-bevacizumab after curative therapy for hepatocellular carcinoma |
title_fullStr | Adjuvant atezolizumab-bevacizumab after curative therapy for hepatocellular carcinoma |
title_full_unstemmed | Adjuvant atezolizumab-bevacizumab after curative therapy for hepatocellular carcinoma |
title_short | Adjuvant atezolizumab-bevacizumab after curative therapy for hepatocellular carcinoma |
title_sort | adjuvant atezolizumab-bevacizumab after curative therapy for hepatocellular carcinoma |
topic | Editorial Commentary |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10282679/ https://www.ncbi.nlm.nih.gov/pubmed/37351140 http://dx.doi.org/10.21037/hbsn-23-203 |
work_keys_str_mv | AT kudomasatoshi adjuvantatezolizumabbevacizumabaftercurativetherapyforhepatocellularcarcinoma |